Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 12, 2009, Pages 3283-3287

  Xu, Wen Ting ^a   Jin, Ning ^a   Xu, Jing ^a   Xu, Yun Gen ^a   Wang, Qiu Juan ^a   You, Qi Dong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Benzoylguanidine derivatives; Myocardial ischemic reperfusion injury; Na+ H+ exchanger inhibitors; Synthesis

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; BENZOYLGUANIDINE DERIVATIVE; BENZYL DERIVATIVE; CARIPORIDE; CREATINE KINASE; GUANIDINE DERIVATIVE; LACTATE DEHYDROGENASE; LACTIC ACID; MALONALDEHYDE; SODIUM PROTON EXCHANGE PROTEIN 1; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; REPERFUSION INJURY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOATES; BLOOD PLATELETS; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GUANIDINES; INHIBITORY CONCENTRATION 50; MYOCARDIAL ISCHEMIA; RATS; SODIUM-HYDROGEN ANTIPORTER;

RATTUS;

EID: 65749109323     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.079     Document Type: Article

References (15)

1. Malo M.E., and Fliegel L. Can. J. Physiol. Pharmacol. 84 (2006) 1081
2. Gross G.J., and Gumina R.J. Drugs Future 26 (2001) 253
3. Slepkov E.R., Rainey J.K., Sykes B.D., and Fliegel L. Biochem. J. 401 (2007) 623
4. Izumi H., Torigoe T., Ishiguchi H., Uramoto H., Yoshida Y., Tanabe M., Ise T., Murakami T., Yoshida T., Nomoto M., and Kohno K. Cancer Treat. Rev. 29 (2003) 541
5. Leineweber K., Heusch G., and Schulz R. Cardiovasc. Drug Rev. 25 (2007) 123
6. Masereel B., Pochet L., and Laeckmann D. Eur. J. Med. Chem. 38 (2003) 547
7. Karmazyn M., Sawyer M., and Fliegel L. Curr. Drug Targets-Cardiovasc. Haematol. Disord. 5 (2005) 323
8. Park H.S., Lee B.K., Park S., Kim S.U., Lee S.H., Baik E.J., Lee S., Yi K.Y., Yoo S.E., Moon C.H., and Jung Y.S. Brain Res. 1061 (2005) 67
9. Zhang R., Lei L., Xu Y.G., Hua W.Y., and Gong G.Q. Bioorg. Med. Chem. Lett. 17 (2007) 2430
10. +.
11. 4), evaporated under reduced pressure, and purified by column chromatography (petroleum ether/acetone, 3:1). The resulting oil was dissolved in acetone and treated with gaseous HCl to afford 5f. Yield: 60%; mp: 231-233 °C.
12. Ting P.C., Umland S.P., Aslanian R., Cao J.-H., Garlisi G.C., Huang Y., Jakway J., Liu Z.-D., Shah H., Tian F., Wan Y.-T., and Shih N.-Y. Bioorg. Med. Chem. Lett. 15 (2005) 3020
13. Rosskopf D., Morgenstern E., Scholz W., Osswald U., and Siffert W. J. Hypertens. 9 (1991) 231
14. Lee B.H., Yi K.Y., and Lee S. Eur. J. Pharmacol. 523 (2005) 101
15. Bak M.I., and Ingwall J.S. Cardiovasc. Res. 57 (2003) 1004